Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (3): 353-360.doi: 10.12092/j.issn.1009-2501.2022.03.016

Previous Articles     Next Articles

Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases

ZHAO Ziwen, FAN Fangtian, JIANG Zhijun   

  1. Jiangsu Changtai Pharmaceuticals, Taizhou 225300, Jiangsu, China
  • Received:2021-12-30 Revised:2022-01-27 Online:2022-03-26 Published:2022-04-11

Abstract: Lung is the breathing organ of the human body. The respiration of the lung enables the body to exchange oxygen with the outside world to maintain the body's life activities. The physiological properties of the lungs expose the mucosal surfaces of the lungs to harmful external irritants, including pathogens, allergens, harmful gases and smoke particles, which can lead to lung injury and infection. Induced by lung inflammation, immune cells (B lymphocytes and T lymphocytes) in the lungs gather around the bronchi, forming induced bronchial associated lymphoid tissue (iBALT). Studies have found that iBALT is involved in the pathological development of asthma, COPD, lung cancer and other lung diseases. iBALT is regulated by a variety of cytokines, but the formation process and its effect on disease remain unclear.  The purpose of this paper is to review the formation factors of iBALT and its pathological status in lung, and to provide new treatment ideas for chronic pulmonary inflammatory diseases. 

Key words: induced bronchial associated lymphoid tissue, chronic obstructive pulmonary disease, asthma, lung cancer

CLC Number: